MFS-16

Primary objective: To evaluate the safety and tolerability of MFS-16 for injection in healthy participants. Secondary objectives: (1) To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of single intravenous administration and continuous intravenous infusion of MFS-16 for injection in healthy participants; (2) To evaluate the effects of single intravenous administration and continuous intravenous infusion of MFS-16 for injection on the QT/QTc interval in healthy participants; (3) To evaluate the substance balance and metabolic transformation of single intravenous administration of MFS-16 for injection in healthy participants.